Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. - Wikidata - awgldk - TriplyDB

Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.

Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.

http://www.wikidata.org/entity/Q40885799

about

Recent advances in the understanding and management of IgA nephropathy Rituximab use in adult primary glomerulopathy: where is the evidence?Effect of Immunosuppressive Drugs on the Changes of Serum Galactose-Deficient IgA1 in Patients with IgA Nephropathy Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: from bench to bedside and beyond.B cell-depleting therapy with rituximab or ofatumumab in immunoglobulin A nephropathy or vasculitis with nephritis.Efficacy and safety of adding mizoribine to standard treatment in patients with immunoglobulin A nephropathy: A randomized controlled trial Corticosteroid Treatment Influences TA-Proteinuria and Renal Survival in IgA Nephropathy.Changes in the clinical presentation of immunoglobulin A nephropathy: data from the Spanish Registry of Glomerulonephritis.Efficacy of Leflunomide, Telmisartan, and Clopidogrel for Immunoglobulin A Nephropathy: A Randomized Controlled Trial.Multiple rare genetic variants co-segregating with familial IgA nephropathy all act within a single immune-related network.Abelmoschus manihot - a traditional Chinese medicine versus losartan potassium for treating IgA nephropathy: study protocol for a randomized controlled trial.Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.Identification of novel molecular signatures of IgA nephropathy through an integrative -omics analysis.Highlights of the 2015 ERA-EDTA Congress--glomerular diseases.Corticosteroids in IgA Nephropathy: Lessons from Recent Studies.Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy?Clinical and histological risk factors for progression of IgA nephropathy: an update in children, young and adult patients.Inflammation in IgA nephropathy.Is there a role for immunosuppression in immunoglobulin A nephropathy?Pro: STOP immunosuppression in IgA nephropathy?Circulating complement factor H-related proteins 1 and 5 correlate with disease activity in IgA nephropathy.In IgA Nephropathy, Glomerulosclerosis Is Associated with Increased Urinary CD80 Excretion and Urokinase-Type Plasminogen Activator Receptor-Positive Podocyturia.A Multicenter Study of the Predictive Value of Crescents in IgA Nephropathy.The effects of cytotoxic therapy in progressive IgA nephropathy.IgA1 Protease Treatment Reverses Mesangial Deposits and Hematuria in a Model of IgA Nephropathy.Omega-3 Polyunsaturated Fatty Acids for the Treatment of IgA Nephropathy.In Acute IgA Nephropathy, Proteinuria and Creatinine Are in the Spot, but Podocyturia Operates in Silence: Any Place for Amiloride?Long-term outcome in 145 patients with assumed benign immunoglobulin A nephropathy.Glomerular disease: Targeted steroid therapy for IgA nephropathy.A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction.Severe Adverse Effects Associated With Corticosteroid Treatment in Patients With IgA Nephropathy.Seasonal proteinuria changes in IgA nephropathy patients after proteinuria remission.Recurrence of primary glomerulonephritis: Review of the current evidence.Recurrence of primary glomerulonephritis: Review of the current evidence.Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy.Immunosuppressive therapy for active IgA nephropathy is effective and safe, even in "elderly" patients.IgA nephropathy with presentation of nephrotic syndrome at onset in children.ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap.The longer the better: follow-up in seemingly 'benign' immunoglobulin A nephropathy.IgA nephropathy in Greece: data from the registry of the Hellenic Society of Nephrology.

P2860

Q26766126-6295DD7C-8AB3-4E11-A92E-9B11FE030C43 Q28075564-75D79891-C3C6-46F7-B533-B0785416E35F Q28554822-042E600C-5F62-4975-B600-320FD1367C81 Q33620537-E86FA5B7-C6FB-40E5-943E-0E69CEB9A9F7 Q33793476-E7F4BB4D-F7A6-40E9-AD13-CADB52A4FC9E Q33853495-F8B14FCB-D521-454A-9639-15035D93B199 Q36077744-08BE958A-5AD4-400E-9826-6AAC27B36EB7 Q36359848-3E94FA98-B307-4908-AE8A-C6725BFEE37B Q37185408-60B2BCF6-B3A2-4F48-9A06-2EA96B645BA4 Q37631861-DD2EBC8D-3B01-4404-862A-E4480F47C74C Q37747625-34F24F7C-4AC2-4700-96E5-3885E964709C Q38372995-84B80EB0-539F-4C43-88DA-F48A0C840EE7 Q38613296-B7B9314D-A308-41B7-AF5A-4784AFE30FBC Q38695675-445C786E-081B-44E1-9B14-7CBE0665E2CC Q38817381-BAB24AA9-3FC2-449A-B641-6457AC76BBD7 Q38860793-313DED09-54BB-4522-A76B-3960B87DF082 Q38999373-035D124E-AFC7-41AF-B419-19791C080D94 Q39178756-97194507-ACE4-4C62-9F25-3C9782D3610F Q39229309-6DD7C955-D260-4B92-B2C0-E67C0A4E4B23 Q39497940-43A28A47-6B8C-4F3C-9FB3-CEA86D8798CE Q40136434-C22A6BEF-3933-4B87-8FAB-4621169CF816 Q40155257-7D821B3C-D837-49C3-84DE-260CEBEA45FF Q40545153-5297B3AB-2261-4B0A-A9D8-227A7E2A9ADB Q40734312-B9505362-10B3-4AC9-8476-D02C77D0C60B Q40974297-B0FA8DD9-13B2-45AB-8E6A-9C5900EBDCF3 Q41161386-067535D6-4C0E-45F4-9657-9860B8A0E4A2 Q42021353-500DC47C-F186-46ED-AA7F-0B158117D328 Q43924057-04415B9F-5AB9-4BE5-AC17-72BDB5BA30BE Q46127906-3008B8B1-2BF7-4747-A182-176631C40C2D Q46606282-3796D238-CDB6-40E0-B3CF-163C8AD7EA12 Q47107237-B4401D79-AA8B-4F74-9230-25A98D11CA28 Q47171676-BD19BB7E-A00C-4127-BA23-7323437C9DDF Q47193282-D6858398-EF14-4868-AECE-08AC58372BB9 Q47243136-18C1F0A4-176D-4FB3-8E48-A078F9ABED8F Q47773361-CB7D9E51-9642-4E79-93F4-C880E9B2E138 Q48148915-136DBF12-FA18-482C-8686-33EE2CD8712A Q48316624-3FD52A09-8E2B-4C26-9D2B-A49C4F7C7135 Q49215238-F56B86E6-AAE5-4B7A-BB10-82C58CE89C59 Q49385716-34423DC0-88AD-494F-8DB6-D802373E8DFE Q49477908-8104E56F-428D-4456-A528-6C8EDFF5BDE5

P2860

Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.

http://www.wikidata.org/entity/Q40885799

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.

@en

type

label

Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.

@en

prefLabel

Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.

@en

P1433

Q40885799-1F746786-5548-4A41-9591-F27CDB78CEEB

P1476

Q40885799-8620BA1E-0011-4E89-B198-B87BA578C08A

P2093

Q40885799-1F390EED-DA8B-46F5-A872-D19AF2EEE11F

Q40885799-2D167FC3-6B26-44F4-8821-6F57294971A3

Q40885799-4DD369FF-1E71-4475-9FA5-75471ACE86D0

Q40885799-530DEBC0-52D7-48D7-9F61-4A90E1C1B4C7

Q40885799-548B49E8-658E-41BD-9E66-FB08FAB05380

Q40885799-5B51CFB9-E0DC-47AD-AADF-6771C8EEACC9

Q40885799-5BC60B0A-7354-4499-89C8-2F3BEDB21DAA

Q40885799-65841C89-F117-4B98-9DB6-077FCBCF23F5

Q40885799-70BD2F5B-57FC-4933-8F64-F7D32DD72F1D

Q40885799-87803D19-28E4-49FE-87D6-047B7F2244CC

P304

Q40885799-9665D589-8AB5-4239-A175-03B62F9A1477

P31

Q40885799-F82900CD-C9DB-427E-8B54-E7B4F237CD35

P356

Q40885799-BA67F6DE-BA11-4447-82E2-96DFDA5F8155

P407

Q40885799-B80939E4-96A5-426D-B5D0-71D417DE4E4B

P433

Q40885799-70F5C20C-1DD5-4695-B5C6-C0A1D9391EAE

P478

Q40885799-E6A39491-C08B-4E56-8131-35E8FAAF3FBB

P50

Q40885799-DD540797-07C1-4810-8F2D-88785AABFBDE

Q40885799-FF1FEAA6-8D91-46F0-9997-9B6D1F489F26

P577

Q40885799-E5079635-F083-4437-ACF9-BAE0D4217722

P698

Q40885799-82E7F2A1-E06A-485D-B758-92A07A7FEAE3

P921

Q40885799-03EA61F4-215E-483D-BAE1-7F2673885703

P356

P1433

The New England Journal of Medicine

P1476

Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.

@en

P2093

Britta Otte

http://www.w3.org/2001/XMLSchema#string

Christina Fitzner

http://www.w3.org/2001/XMLSchema#string

Claudia Sommerer

http://www.w3.org/2001/XMLSchema#string

Frank Eitner

http://www.w3.org/2001/XMLSchema#string

Johannes F E Mann

http://www.w3.org/2001/XMLSchema#string

Jürgen Floege

http://www.w3.org/2001/XMLSchema#string

Martin Zeier

http://www.w3.org/2001/XMLSchema#string

Oliver Gross

http://www.w3.org/2001/XMLSchema#string

Oliver Witzke

http://www.w3.org/2001/XMLSchema#string

Peter R Mertens

http://www.w3.org/2001/XMLSchema#string

P304

2225-2236

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1415463

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

373

http://www.w3.org/2001/XMLSchema#string

P50

Ralf-Dieter Hilgers

P577

2015-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26630142

http://www.w3.org/2001/XMLSchema#string

P921

immunosuppression